Downing v. Astrazeneca Pharmaceuticals LP

CourtDistrict Court, M.D. Tennessee
DecidedJuly 20, 2023
Docket3:22-cv-00447
StatusUnknown

This text of Downing v. Astrazeneca Pharmaceuticals LP (Downing v. Astrazeneca Pharmaceuticals LP) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Downing v. Astrazeneca Pharmaceuticals LP, (M.D. Tenn. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

GAIL DOWNING, ) ) Plaintiff, ) ) NO. 3:22-cv-00447 v. ) ) JUDGE CAMPBELL ASTRAZENECA ) MAGISTRATE JUDGE HOLMES PHARMACEUTICALS LP, ) ) Defendant. )

MEMORANDUM Pending before the Court is Defendant AstraZeneca Pharmaceuticals LP’s (“AstraZeneca”) Partial Motion to Dismiss. (Doc. No. 21). Plaintiff Gail Downing filed a Response (Doc. No. 26), and Defendant filed a Reply (Doc. No. 27). For the reasons stated, Defendant’s motion to dismiss will be GRANTED in part, and DENIED in part. I. BACKGROUND1 Plaintiff Gail Downing was employed by AstraZeneca as a sales manager. (Am. Compl., Doc. No. 15, ¶¶ 8-12). In her capacity as sales manager, Plaintiff received a report that a sales representative under her supervision (the “Co-Worker”) showed a sexually explicit photograph of a minor to a provider during a company visit and told the provider about her sexual relationship with the person depicted in the photograph. (Id., ¶¶ 12-14). Plaintiff also learned that the Co- Worker shared information with another AstraZeneca sales representative about that sexual relationship. (Id., ¶ 19).

1 All facts are as alleged in the Amended Complaint. (Doc. No. 15). Plaintiff reported these incidents to the human resources department at AstraZeneca.2 (Id., ¶ 27). AstraZeneca began an investigation, but the investigation was put on hold because the Co- Workers was on leave. (Id., ¶ 29). When the Co-Worker returned to work several months later, she made allegations against Plaintiff and others. (Id., ¶ 31). AstraZeneca investigated the Co-Worker’s allegations. (Id.).

Ultimately, Plaintiff was fired and replaced by a younger employee, and the Co-Worker, who was significantly younger than Plaintiff, continued to work for AstraZeneca. (Id., ¶¶ 36, 37, 48). Plaintiff brings state and federal law claims for age discrimination and retaliation – specifically: (1) age discrimination and retaliation in violation of Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000e, et seq. (Count 1); (2) age discrimination and retaliation in violation of the Tennessee Human Rights Act, Tenn. Code Ann. §§ 4-21-101, et seq. (Count 2); (3) retaliatory discharge under Tennessee common law (Count 3); (4) retaliation in violation of the Tennessee Public Protection Act, Tenn. Code Ann. §§ 50-1-304 (Count 4); and (5) age discrimination in violation of the Age Discrimination in Employment Act (“ADEA”), 29 U.S.C.

§§ 621, et seq. (Count 5). Defendant moves to dismiss Counts 1, 3, and 4.

2 The Amended Complaint does not state whether Plaintiff informed AstraZeneca about the Co- Workers’s communications with the AstraZeneca sales agent or if her report only concerned the incidents with providers. However, because Plaintiff alleges AstraZeneca interviewed Brice Roberts as part of its investigation, the Court will construe the Amended Complaint to allege that Plaintiff also reported that the Co-Worker told Brice Roberts that she (Co-Worker) was having a sexual relationship with a minor. II. STANDARD OF REVIEW For purposes of a motion to dismiss, the Court must take all of the factual allegations in the complaint as true. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face. Id. A claim has facial plausibility when the plaintiff pleads factual content

that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged. Id. Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice. Id. When there are well-pleaded factual allegations, a court should assume their veracity and then determine whether they plausibly give rise to an entitlement to relief. Id. at 679. A legal conclusion, including one couched as a factual allegation, need not be accepted as true on a motion to dismiss, nor are mere recitations of the elements of a cause of action sufficient. Id. at 678; Fritz v. Charter Twp. of Comstock, 592 F.3d 718, 722 (6th Cir. 2010); Abriq v. Hall, 295 F. Supp. 3d 874, 877 (M.D. Tenn. 2018). Moreover, factual allegations that are merely consistent with the defendant’s liability do not satisfy the claimant’s burden, as mere

consistency does not establish plausibility of entitlement to relief even if it supports the possibility of relief. Iqbal, 556 U.S. at 678. III. ANALYSIS A. Title VII Title VII prohibits an employer from discriminating against an individual with respect to “compensation, terms, conditions, or privileges of employment, because of such individual’s race, color, religion, sex, or national origin.” 42 U.S.C. § 2000e-2(a)(1). Title VII also prohibits an employer from “discriminat[ing] against any of [its] employees … because [an employee] has opposed any practice made an unlawful employment practice by [Title VII], or because the employee has made a charge, testified, assisted, or participated in any manner in an investigation, proceeding, or hearing under [Title VII].” 42 U.S.C. § 2000e-3(a). Title VII Plaintiffs need not allege the elements of a prima facie case under the familiar McDonnell Douglas framework to avoid dismissal. Charlton-Perkins v. Univ. of Cincinnati, 35 F.4th 1053, 1060 (6th Cir. 2022) (citing Swierkiewicz v. Sorema N.A., 534 U.S. 506, 512 (2002)).

A complaint alleging retaliation claims need only allege facts sufficient to allow the court to “draw the reasonable inference” that the employer discriminated or retaliated against the plaintiff. Keys v. Humana, 684 F.3d 605, 610 (6th Cir. 2012). The retaliation, however, must be tied to Plaintiff opposing a practice made unlawful under Title VII or making a charge or participating in a Title VII investigation or proceeding. See 42 U.S.C. § 2000e-3(a). This activity – opposing a practice made unlawful under Title VII or making a charge or otherwise participating in a Title VII investigation – is generally referred to as “protected activity.” Importantly, the “protected activity” must involve conduct between an employer and an employee. See Stanley v. ExpressJetAirlines, Inc., 808 F. App’x 351, 357 (6th Cir. 2020) (“[T]he key question is whether the complaint concerns

conduct between an employer and its employee.”) (quoting David. C. Singer and Joshua Colangelo-Bryan, Protected Activity Under Title VII Retaliation Claims, 231 N.Y.L.J. 2 (Feb. 6, 2004)). If the alleged basis of the retaliation is not plausibly related to Title VII, a retaliation claim under Title VII fails.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Swierkiewicz v. Sorema N. A.
534 U.S. 506 (Supreme Court, 2002)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Kathryn Keys v. Humana, Inc.
684 F.3d 605 (Sixth Circuit, 2012)
Williams v. Greater Chattanooga Public Television Corp.
349 S.W.3d 501 (Court of Appeals of Tennessee, 2011)
Mason v. Seaton
942 S.W.2d 470 (Tennessee Supreme Court, 1997)
Fritz v. Charter Township of Com-Stock
592 F.3d 718 (Sixth Circuit, 2010)
Charles Haynes v. Formac Stables, Inc.
463 S.W.3d 34 (Tennessee Supreme Court, 2015)
Williams v. City of Burns
465 S.W.3d 96 (Tennessee Supreme Court, 2015)
Mark Charlton-Perkins v. Univ. of Cincinnati
35 F.4th 1053 (Sixth Circuit, 2022)
Abriq v. Hall
295 F. Supp. 3d 874 (M.D. Tennessee, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Downing v. Astrazeneca Pharmaceuticals LP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/downing-v-astrazeneca-pharmaceuticals-lp-tnmd-2023.